- Home
- GSBC vs ITRM Comparison
GSBC vs ITRM Comparison
Compare GSBC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- ITRM
- Stock Information
- Founded
- GSBC 1923
- ITRM 2015
- Country
- GSBC United States
- ITRM Ireland
- Employees
- GSBC N/A
- ITRM N/A
- Industry
- GSBC Major Banks
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- ITRM Health Care
- Exchange
- GSBC Nasdaq
- ITRM Nasdaq
- Market Cap
- GSBC N/A
- ITRM 37.7M
- IPO Year
- GSBC N/A
- ITRM 2018
- Fundamental
- Price
- GSBC $54.79
- ITRM $1.26
- Analyst Decision
- GSBC Hold
- ITRM Strong Buy
- Analyst Count
- GSBC 2
- ITRM 1
- Target Price
- GSBC $59.50
- ITRM $5.00
- AVG Volume (30 Days)
- GSBC 38.4K
- ITRM 382.6K
- Earning Date
- GSBC 04-16-2025
- ITRM 05-12-2025
- Dividend Yield
- GSBC 2.89%
- ITRM N/A
- EPS Growth
- GSBC 10.51
- ITRM N/A
- EPS
- GSBC 5.60
- ITRM N/A
- Revenue
- GSBC $219,572,000.00
- ITRM N/A
- Revenue This Year
- GSBC N/A
- ITRM N/A
- Revenue Next Year
- GSBC $2.27
- ITRM $150.10
- P/E Ratio
- GSBC $9.78
- ITRM N/A
- Revenue Growth
- GSBC N/A
- ITRM N/A
- 52 Week Low
- GSBC $47.57
- ITRM $0.81
- 52 Week High
- GSBC $68.02
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- GSBC 51.83
- ITRM 52.71
- Support Level
- GSBC $50.95
- ITRM $1.01
- Resistance Level
- GSBC $57.68
- ITRM $1.42
- Average True Range (ATR)
- GSBC 2.30
- ITRM 0.09
- MACD
- GSBC 0.57
- ITRM 0.03
- Stochastic Oscillator
- GSBC 65.47
- ITRM 60.98
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.